Share

November 2021; 8 (6) ArticleOpen Access

Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome

Jonathan D. Santoro, Lauren M. Kerr, Rachel Codden, Theron Charles Casper, Benjamin M. Greenberg, Emmanuelle Waubant, Sek Won Kong, Kenneth D. Mandl, Mark P. Gorman
First published September 2, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001079
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
619

Share

Article Information

vol. 8 no. 6 e1079
DOI: 
https://doi.org/10.1212/NXI.0000000000001079
PubMed: 
34475249
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 5, 2021
  • Accepted in final form June 8, 2021
  • First Published September 2, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Jonathan D. Santoro, MD,
    2. Lauren M. Kerr, BA (lauren.kerr{at}cardio.chboston.org),
    3. Rachel Codden, MPH (rachel.codden{at}hsc.utah.edu),
    4. Theron Charles Casper, PhD (charlie.casper{at}hsc.utah.edu),
    5. Benjamin M. Greenberg, MD (benjamin.greenberg{at}utsouthwestern.edu),
    6. Emmanuelle Waubant, MD, PhD (emmanuelle.waubant{at}ucsf.edu),
    7. Sek Won Kong, MD (sekwon.kong{at}childrens.harvard.edu),
    8. Kenneth D. Mandl, MD, MPH (kenneth.mandl{at}childrens.harvard.edu) and
    9. Mark P. Gorman, MD (mark.gorman{at}childrens.harvard.edu)
  1. Jonathan D. Santoro, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Lauren M. Kerr, BA (lauren.kerr{at}cardio.chboston.org),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Rachel Codden, MPH (rachel.codden{at}hsc.utah.edu),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Theron Charles Casper, PhD (charlie.casper{at}hsc.utah.edu),
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Aperta Biosciences

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. F. Hoffmann-La Roche Ltd

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1)National Multiple Sclerosis Society, #SI-1808-32326, Principal Investigator, 2013-2022

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Benjamin M. Greenberg, MD (benjamin.greenberg{at}utsouthwestern.edu),
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Greenberg has filed patents on the use of antibody biology in multiple sclerosis

    Publishing Royalties:

    1. Transverse Myelitis, UpToDate

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Novartis, Alexion, EMD Serono, Genentech, Viela Bio, Rubin Anders

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. CLENE Nanomedicine, Anokion

    Research Support, Government Entities:

    1. NIH RO1 NS071463, Co-investigator 2012-14, PCORI, PI, 2013-2020

    Research Support, Academic Entities:

    1. Unviersity of Texas Southwestern

    Research Support, Foundations and Societies:

    1. Guthy Jackson Foundation, Siegel Rare Neuroimmune Association, National MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Expert witness in patent litigation involving Mylan

  6. Emmanuelle Waubant, MD, PhD (emmanuelle.waubant{at}ucsf.edu),
    7. Scientific Advisory Boards:

    1. I volunteer on a Novartis advisory board (pharmaceutical company)for a clinical trial

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. MS at the Limit provided me travel to give a talk in 2020

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Demyelinating disorders of the central nervous system in childhood. Cambridge University. 2011 Pediatric MS and related disorders. 2017

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I am site PI for trials of ocrelizumab in PPMS (Roche, company), fumaric acid in RRMS (Biogen, company) and with Alexion in NMOSD

    Research Support, Government Entities:

    1. I am co-PI for a trial sponsored by PCORI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. I am supported by the National MS Society RG4861A3/1 (PI Waubant), NIH, PCORI and the Race to Erase MS (medical director)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Sek Won Kong, MD (sekwon.kong{at}childrens.harvard.edu),
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Scientific Reports, Editorial Board, 2019-current

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Pfizer

    Research Support, Government Entities:

    1. NIH/NIMH, R01MH107205, PI, 2015-2021 NIH/NHGRI, U01HG007530, Co-I, 2018-2021 NIH/NCATS, 1U01TR002623, Co-I, 2019-2024 NIH/ORIP, 5R24OD024622, MPI, 2018-2022

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Kenneth D. Mandl, MD, MPH (kenneth.mandl{at}childrens.harvard.edu) and
    9. Scientific Advisory Boards:

    1. Ciox.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Merck.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Gates Foundation. Department of Health and Human Services. Moorehouse School of Medicine.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Activate Care; Ciox.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Mark P. Gorman, MD (mark.gorman{at}childrens.harvard.edu)
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Pfizer, (2) Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society (Grant numbers SI-1808- 32326, 16-A0-00-006699-01, RG-1701-26635)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA.
  1. Correspondence
    Dr. Santoro jdsantoro{at}chla.usc.edu

Article usage

Article usage: September 2021 to October 2023

AbstractFullPdfSource
Sep 202112714152Highwire
Oct 20211113440Highwire
Nov 2021713546Highwire
Dec 202139620Highwire
Jan 202247515Highwire
Feb 202237828Highwire
Mar 202208234Highwire
Apr 202224013Highwire
May 202234214Highwire
Jun 202246423Highwire
Jul 202226511Highwire
Aug 202236915Highwire
Sep 202257827Highwire
Oct 202244417Highwire
Nov 2022511727Highwire
Dec 2022310512Highwire
Jan 2023510811Highwire
Feb 202339014Highwire
Mar 2023310113Highwire
Apr 202334714Highwire
May 202333917Highwire
Jun 202342115Highwire
Jul 202312016Highwire
Aug 202322014Highwire
Sep 20232385Highwire
Oct 20231276Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles